ArticleEvidence-based complementary and alternative medicine : eCAM2022
PEGylated Magnetite/Hydroxyapatite: A Green Nanocomposite for T2-Weighted MRI and Curcumin Carrying.
Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Curcumin as theranostics: imaging-guided therapeutics in oncology and neurodegenerative diseases.Frontiers in nutrition · 2026Review
- Magnetic Resonance Imaging, Fluorescence, and Drug Release Properties of Curcumin-Loaded PEGylated Magnetite@Graphene Quantum Dots Nanocomposite.Journal of biomedical physics & engineering · 2025Article
- PVA-Cellulose Fibers Composites Impregnated with Antimicrobial Particles: The Solvent Effect.Polymers · 2025Article
- Comparison of X-Ray Attenuation Performance, Antimicrobial Properties, and Cytotoxicity of Silicone-Based Matrices Containing BiJournal of biomedical physics & engineering · 2024Article
- Hydroxyapatite Biobased Materials for Treatment and Diagnosis of Cancer.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The design of new magnetic resonance imaging (MRI) contrast media with chemotherapy drug-carrying capacity has an important role in diagnostic and therapeutic purposes. This study aimed to synthesize a polyethylene glycol (PEG)-coated magnetite/hydroxyapatite nanocomposite as an MRI contrast agent investigate its curcumin loading/release properties and consider the cytotoxicity effect of the curcumin-loaded nanocomposite on different cell lines. Materials and Methods: PEGylated magnetite/hydroxyapatite (PMHA) nanocomposite was synthesized and characterized using Results: The spherical nanocomposite showed an average size of 20 nm and a superparamagnetic property. PMHA nanocomposite was highly cytocompatible, while the curcumin-loaded nanocomposite showed significant cytotoxicity for A549 and a much higher toxic effect on MCF-7 cancer cells. The r2 relaxivity was measured as 120 mM Conclusion: The high r2 relaxivity of PMHA nanocomposite and sustained release of curcumin from the loaded one at the pH of tumor environment suggest that the nanocomposite is a potential candidate for T2-weighted MRI and cancer treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.